Faculty Information - SHINMURA Hiroaki

（Last updated : 2025-11-21 11:01:54）

SHINMURA Hiroaki
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Assistant Professor

■ Published papers

1.	Original article	Long-term real-world outcomes of nivolumab plus ipilimumab for advanced renal cell carcinoma: a minimum of 4-years follow-up study. 2025/09
2.	Original article	Outcomes of enfortumab vedotin treatment in patients ineligible for the EV‐301 trial. 2025/09
3.	Original article	Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma. 2025/08
4.	Other	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. 2025/05
5.	Original article	Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group. 2025/04
6.	Original article	Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in Japan. 2025/04
7.	Original article	Changes in outcome of patients with advanced non‑clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno‑oncology era. 2024/11
8.	Original article	Prognostic impact of the administration of antibiotics and proton pump inhibitors in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. 2024/07/03
9.	Original article	Survival impact of glucocorticoid administration for adverse events during immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. 2024/07
10.	Original article	Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up. 2024/05/07
11.	Original article	Association between kidney function and outcomes following immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell carcinoma. 2024/04
12.	Original article	First‑line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the efectiveness using real‑world data. 2024/04
13.	Original article	Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2023/07
14.	Review article	Impact of sex on prognosis in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. 2023/07
15.	Original article	An examination of the relationship between satisfaction with overactive bladder (OAB) treatment and the doctor–patient gender: A questionnaire-based single-institution study. 2023/03/25
16.	Original article	Comparison of outcomes between therapeutic combinations based on immune checkpoint inhibitors or tyrosine kinase inhibitor monotherapy for first-line therapy of patients with advanced renal cell carcinoma outside of clinical trials: A real-world retrospective multi-institutional study. 2023/03
17.	Original article	Impact of body mass index on outcomes in an asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. 2023/02
18.	Original article	Comparison of the impact of immune-related adverse events due to immune checkpoint inhibitor dual combination therapy and immune checkpoint inhibitor plus tyrosine kinase inhibitor combination therapy in patients with advanced renal cell carcinoma. 2023/01
19.	Original article	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy of Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria 2022/07/05
20.	Original article	Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. 2022/01
21.	Original article	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. 2021/12
22.	Original article	Prognostic impact of early treatment interruption of nivolumab plus ipilimumab due to immune-related adverse events as first-line therapy for metastatic renal cell carcinoma: A multi-institution retrospective study. 2021/07
23.	Original article	Assessment of understanding of urinary incontinence and its medical intervention in residents od a city affected by the Great East Japan Earthquake disaster 2017
24.	Original article	Whole body counter assessment of internal radiocontamination in patients with end-stage renal disease living in areas affected by the Fukushima Daiichi nuclear power plant disaster: a retrospective observational study. 2015/12
25.	Original article	Minimal internal radiation exposure in residents living south of the fukushima daiichi nuclear power plant disaster. 2015/10
26.	Original article	Whole-body counter surveys of over 2700 babies and small children in and around Fukushima Prefecture 33 to 49 months after the Fukushima Daiichi NPP accident. 2015/10
27.	Original article	Potential role of host effector memory CD8+ T cells in marrow rejection after mixed chimerism induction in cynomolgus monkeys 2010/08
28.	Case report	Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. 2010/02
29.	Original article	Analysis of Renal Transplant Protocol Biopsies in ABO-Incompatible Kidney Transplantation 2008/01
30.	Original article	Evaluation of Immunosuppressive Regimens in ABO-Incompatible Living Kidney Transplantation-Single Center Analysis 2007/04
Display 5 items
Display all(30)

■ Academic conference presentation

1.	Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
2.	Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma. （Poster notice，General） 2025/04/28
3.	Impact of corticosteroid administration on treatment effectiveness in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor-based combination therapy. （Poster notice，General） 2024/05/03
4.	Impact of gender on the efficacy of immune checkpoint inhibitor therapy in renal cell carcinoma. （Poster notice） 2024/04/27
5.	Therapeutic efficacy of Cabozantinib or Axitinib rechallenge for advanced renal cell carcinoma. （Poster notice，General） 2024/04/27
6.	Antibiotic and proton pump inhibitor use and survival of patients receiving immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma. （Poster notice） 2024/04/26
7.	Clinical study of RAPN between RENAL Nephrometry Score 2-2-3-3 and 1-3-3-3. （Poster notice，General） 2024/04/26
8.	Impact of steroids for immune-related adverse events in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. （Poster notice） 2024/04/26
9.	Outcome comparison of IO-IO versus IO-TKI combination therapy for patients with advanced renal cell carcinoma. （Poster notice） 2024/04/26
10.	Comparison of the impacts of immune-related adverse events on the prognosis of patients with advanced renal cell carcinoma between patients treated with IO-IO and IO-TKI combination therapy.. （Poster notice，General） 2023/04/29
11.	Outcome change in patients with advanced renal celcarcinoma outside of clinicalal trials from the tyrosine-kinase inhibitor era to the immune checkpoint inhibitor era. （Poster notice，General） 2023/04/29
12.	Retrospective comparative analysis of urinary incontinence in robotic prostatectomy with combination of umbilical ligament preservation and hood technique. （Speech，General） 2023/04/22
13.	An examination of the relationship between satisfaction with overactive bladder treatment and the doctor-patient gender: a questionnaire-based study. （Poster notice，General） 2023/04/20
14.	Outcome in patients with advanced renal cell carcinoma treated with immunotherapy vs. tyrosine kinase inhibitor based on the status of chronic kidney disease. （Speech，General） 2023/04/20
15.	Association between immune adverse events and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab. （Poster notice，General） 2022/05/13
16.	Effects of first-line immune checkpoint inhibitors in patients with metastatic renal cell carcinoma not meeting trial eligibility criteria. （Poster notice，General） 2022/05/13
17.	Potential survival benefit of deferred nephrectomy in patients treated with nivolumab plus ipilimumab for metastatic renal cell carcinoma. （Poster notice，General） 2022/05/13
18.	Impact of umbilical ligament preservation technique for robotic prostatectomy on urinary incontinence. 2020/12/22
19.	A case of hepatitis B virus transmission in kidney transplantation recipient from hepatitis B core antibody-positive and hepatitis B DNA-negative donor. （Poster notice，General） 2019/09/15
20.	Long-term results of a case of ABO incompatible kidney transplantation with high titer of anti-ABO antibody using eculizumab induction. （Speech，General） 2017/09/26
21.	Evaluation of the understanding of treatment for urinary incontinence in Iwaki city. （Speech，General） 2017/04/22
22.	Excellent long-term outcome of kidney transplantation at a small local hospital, The TOKIWA-KAI foundation JYOBAN hospital in FUKUSHIMA. （Poster notice，General） 2015/09/13
23.	Successful ABO-blood group incompatible kidney transplantation under eculizumab induction. （Poster notice，General） 2015/09/13
24.	A case of hepatitis B virus transmission in kidney transplantation recipient from hepatitis B core antibody-positive and hepatitis B DNA-negative donor. （Poster notice，General） 2015/08/26
25.	A successful case of ABO incompatible kidney transplantation with high anti-blood type antibody titer using eculizumab induction protocol. （Poster notice，General） 2015/08/25
26.	Supporting activity for retroperitoneoscopic living-donor nephrectomy in JAKARTA hospital from JAPAN. （Poster notice，General） 2015/08/24
27.	An Open Label, Prospecive Randomized Controlled Study Comparing Tacrolimus Once-Daily and Twice-Daily in De Novo Kidney Transplatation: Pharmacokinetics and Pathological Analysis by Protocol Biopsy （Speech，General） 2012/06/03
Display 5 items
Display all(27)

■ Social activities

2018/04

Fukushima doctor visits elderly patients dressed as period drama characters

■ Education

1.	2001/04～2005/03	〔Doctoral course〕〔Doctorial Course〕, Graduate School, Division of Medicine, Tokyo Women's Medical University, Completed,
2.	1986/04～1993/03	Graduate School, Division of Medicine, Toyama Medical and Pharmaceutical University, Graduated,